v3.26.1
Revenue from Contracts with Customers
 12 Months Ended
Apr. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue from Contracts with Customers Revenue from Contracts with Customers
Oncology Revenue

The following table represents disaggregated revenue for the twelve months ended April 30, 2026 and 2025:
Year Ended April 30,
 20262025
Pharmacology services$57,133 $48,585 
TOS data license revenue 764 4,676 
Other TOS revenue1,528 3,683 
Total oncology revenue$59,425 $56,944 
TOS data license revenue represents revenue from the sale of a license to access certain of the Company's PDX data. Other TOS revenue represents additional services provided to the Company's pharmaceutical and biotechnology customers, specifically flow cytometry services and software-as-a-service ("SaaS") provided via our Lumin Bioinformatics software.

Contract Balances
Contract assets include unbilled amounts typically resulting from revenue recognized in excess of the amounts billed to the customer for which the right to payment is subject to factors other than the passage of time. These amounts may not exceed their net realizable value. Contract assets are classified as current. Contract liabilities consist of customer payments received in advance of performance and billings in excess of revenue recognized, net of revenue recognized from the balance at the beginning of the period. Contract assets and liabilities are presented on the balance sheet on a net contract-by-contract basis at the end of each reporting period. Refer to Note 3 for related balances.